trial · primary record
Olaparib
Prostate
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 51 |
| Primary completion | 2027-05-01 |
| Primary endpoint | PSA50 Response Rate to Olaparib for Patients With High-risk Biochemically-recurrent Prostate Cancer |
| Registry ID | NCT03047135 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:19.882Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03047135
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.